This innovative Pharma company launches Thiamine Hydrochloride Injection USP in the United States!

The company holds a leadership position in cardiovascular, anti-diabetic and respiratory segments and is the third-largest pharmaceutical company in the U.S. by prescriptions.

Lupin is an innovative pharmaceutical company headquartered in Mumbai, India. It develops and markets a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets worldwide. The company holds a leadership position in cardiovascular, anti-diabetic and respiratory segments and is the third-largest pharmaceutical company in the U.S. by prescriptions. The company prioritises research and development, investing 7.9 per cent of its revenue in FY23.  

Lupin, a global pharmaceutical company, has announced the launch of Thiamine Hydrochloride Injection USP, following the approval of its alliance partner Caplin Steriles Limited's ANDA by the U.S. FDA. This injection is therapeutically equivalent to the reference listed drug of Fresenius Kabi USA LLC. The Thiamine Hydrochloride Injection USP had estimated annual sales of USD 35 million in the U.S. according to IQVIA MAT April 2023.  

The company has delivered returns of 36 per cent of the last 1 year and negative returns of 9.5 per cent over the past 3 years. Additionally, the company maintains a healthy dividend payout ratio of 18.2 per cent.  

On Monday, shares of Lupin Ltd plunged by 0.52 per cent to Rs. 826.55 from its previous close of Rs 830.85.  

Investors should keep a close eye on this trending pharma stock.